UNLABELLED: This consensus article reviews the diagnosis and treatment of osteoporosis in geriatric populations. Specifically, it reviews the risk assessment and intervention thresholds, the impact of nutritional deficiencies, fall prevention strategies, pharmacological treatments and their safety considerations, the risks of sub-optimal treatment adherence and strategies for its improvement. INTRODUCTION: This consensus article reviews the therapeutic strategies and management options for the treatment of osteoporosis of the oldest old. This vulnerable segment (persons over 80 years of age) stands to gain substantially from effective anti-osteoporosis treatment, but the under-prescription of these treatments is frequent. METHODS: This report is the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores some of the reasons for this and presents the arguments to counter these beliefs. The risk assessment of older individuals is briefly reviewed along with the differences between some intervention guidelines. The current evidence on the impact of nutritional deficiencies (i.e. calcium, protein and vitamin D) is presented, as are strategies to prevent falls. One possible reason for the under-prescription of pharmacological treatments for osteoporosis in the oldest old is the perception that anti-fracture efficacy requires long-term treatment. However, a review of the data shows convincing anti-fracture efficacy already by 12 months. RESULTS: The safety profiles of these pharmacological agents are generally satisfactory in this patient segment provided a few precautions are followed. CONCLUSION: These patients should be considered for particular consultation/follow-up procedures in the effort to convince on the benefits of treatment and to allay fears of adverse drug reactions, since poor adherence is a major problem for the success of a strategy for osteoporosis and limits cost-effectiveness.
UNLABELLED: This consensus article reviews the diagnosis and treatment of osteoporosis in geriatric populations. Specifically, it reviews the risk assessment and intervention thresholds, the impact of nutritional deficiencies, fall prevention strategies, pharmacological treatments and their safety considerations, the risks of sub-optimal treatment adherence and strategies for its improvement. INTRODUCTION: This consensus article reviews the therapeutic strategies and management options for the treatment of osteoporosis of the oldest old. This vulnerable segment (persons over 80 years of age) stands to gain substantially from effective anti-osteoporosis treatment, but the under-prescription of these treatments is frequent. METHODS: This report is the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores some of the reasons for this and presents the arguments to counter these beliefs. The risk assessment of older individuals is briefly reviewed along with the differences between some intervention guidelines. The current evidence on the impact of nutritional deficiencies (i.e. calcium, protein and vitamin D) is presented, as are strategies to prevent falls. One possible reason for the under-prescription of pharmacological treatments for osteoporosis in the oldest old is the perception that anti-fracture efficacy requires long-term treatment. However, a review of the data shows convincing anti-fracture efficacy already by 12 months. RESULTS: The safety profiles of these pharmacological agents are generally satisfactory in this patient segment provided a few precautions are followed. CONCLUSION: These patients should be considered for particular consultation/follow-up procedures in the effort to convince on the benefits of treatment and to allay fears of adverse drug reactions, since poor adherence is a major problem for the success of a strategy for osteoporosis and limits cost-effectiveness.
Authors: Adolfo Díez-Pérez; Jose M Olmos; Xavier Nogués; Manuel Sosa; Manuel Díaz-Curiel; Jose Luis Pérez-Castrillón; Ramon Pérez-Cano; Manuel Muñoz-Torres; Antonio Torrijos; Esteban Jodar; Luis Del Rio; Jose R Caeiro-Rey; Jordi Farrerons; Joan Vila; Claude Arnaud; Jesus González-Macías Journal: J Bone Miner Res Date: 2012-04 Impact factor: 6.741
Authors: K E Ensrud; D M Black; L Palermo; D C Bauer; E Barrett-Connor; S A Quandt; D E Thompson; D B Karpf Journal: Arch Intern Med Date: 1997 Dec 8-22
Authors: S C E Schuit; M van der Klift; A E A M Weel; C E D H de Laet; H Burger; E Seeman; A Hofman; A G Uitterlinden; J P T M van Leeuwen; H A P Pols Journal: Bone Date: 2004-01 Impact factor: 4.398
Authors: Heike A Bischoff-Ferrari; Douglas P Kiel; Bess Dawson-Hughes; John E Orav; Ruifeng Li; Donna Spiegelman; Thomas Dietrich; Walter C Willett Journal: J Bone Miner Res Date: 2009-05 Impact factor: 6.741
Authors: Kristine E Ensrud; Susan K Ewing; Brent C Taylor; Howard A Fink; Katie L Stone; Jane A Cauley; J Kathleen Tracy; Marc C Hochberg; Nicolas Rodondi; Peggy M Cawthon Journal: J Gerontol A Biol Sci Med Sci Date: 2007-07 Impact factor: 6.053
Authors: R Rizzoli; C-L Benhamou; J Halse; P D Miller; I R Reid; J A Rodríguez Portales; C DaSilva; R Kroon; N Verbruggen; A T Leung; D Gurner Journal: Osteoporos Int Date: 2016-02-15 Impact factor: 4.507
Authors: E Cavalier; P Bergmann; O Bruyère; P Delanaye; A Durnez; J-P Devogelaer; S L Ferrari; E Gielen; S Goemaere; J-M Kaufman; A Nzeusseu Toukap; J-Y Reginster; A-F Rousseau; S Rozenberg; A J Scheen; J-J Body Journal: Osteoporos Int Date: 2016-03-30 Impact factor: 4.507
Authors: H Blain; T Masud; P Dargent-Molina; F C Martin; E Rosendahl; N van der Velde; J Bousquet; A Benetos; C Cooper; J A Kanis; J Y Reginster; R Rizzoli; B Cortet; M Barbagallo; K E Dreinhöfer; B Vellas; S Maggi; T Strandberg Journal: J Nutr Health Aging Date: 2016 Impact factor: 4.075